https://doi.org/10.4081/hmr.v2i5.381

Bortezomib-combination based therapy in relapsed-refractory myeloma patients

Vol. 2 No. 5: Bortezomib (Velcade®) in multiple myeloma: an update
Published: June 8, 2009
Abstract Views: 233
PDF: 1369
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Patrizia Zappasodi
support@pagepress.org
The encouraging results obtained by Bortezomib (Velcade®) as single agent in relapsed-resistant multiple myeloma (MM) patients has brought to test effective combinations with conventional myeloma agents in order to improve the response and the survival of this difficult setting of patients. The main action of Bortezomib (Velcade®) is the inhibition of the transcription factor NF-kB, down regulating the expression of several apoptosis inhibitors, and inducing apoptosis of drug resistant multiple myeloma cell lines. Moreover, the inhibition of NF-kB determines a down regulated transcription of several effectors of the protective cellular response to genotoxic stress, like topoisomerase II beta. As a consequence, Bortezomib (Velcade®) sensitizes myeloma cells to chemotherapy and overcomes resistance to genotoxic agents.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Zappasodi, P. (2009). Bortezomib-combination based therapy in relapsed-refractory myeloma patients. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.381
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).